文献速递神经肿瘤

红外光谱临床转化的新途径:利用胶质母细胞瘤特征谱识别泛脑肿瘤

A new approach for clinical translation of infrared spectroscopy: exploitation of the signature of glioblastoma for general brain tumor recognition.
PubMed 文献 · J Neurooncol · 2022-12-12

研究对790例新鲜标本行衰减全反射红外光谱,基于胶质母细胞瘤(n=135)与非肿瘤脑组织(n=27)建立分类模型并应用于多类脑肿瘤。模型对肿瘤与非肿瘤分类正确率为82%(517/628),识别胶质母细胞瘤、其他原发脑肿瘤及脑转移瘤的准确率分别为86%、92%、92%,全部非肿瘤样本均被正确识别。

要点

  • 基于胶质母细胞瘤光谱特征建立的模型对肿瘤与非肿瘤分类正确率为82%(517/628)。
  • 该模型识别胶质母细胞瘤准确率86%,其他原发脑肿瘤92%,脑转移瘤92%。
  • 全部非肿瘤样本均被正确识别,但浸润性胶质瘤的敏感性有限。

核心结论

  • 基于共同光谱肿瘤特征区分脑肿瘤与非肿瘤脑组织的概念将加速红外光谱及相关技术的临床转化。
  • 未来临床场景中外科医生可用单一设备术中检测多种脑肿瘤类型。
  • 数据提示此举伴随漏检浸润区域或肿瘤的某些风险,但不伴随切除非肿瘤脑组织的风险。

研究设计与样本

  • 对790例患者切除后数分钟内的新鲜标本行衰减全反射红外光谱检测。
  • 采用主成分分析与线性判别分析,在胶质母细胞瘤(n=135)与非肿瘤脑组织(n=27)子集上建立分类模型,再应用于多类脑肿瘤红外光谱的分类。

主要发现

  • 模型将82%(517/628)的标本正确分类为「肿瘤」或「非肿瘤」。
  • 模型识别胶质母细胞瘤的准确率为86%,其他类型原发脑肿瘤为92%,脑转移瘤为92%。
  • 全部非肿瘤样本均被正确识别。
  • 该模型对浸润性胶质瘤的敏感性有限。

临床怎么用

  • 原文结论指出,未来临床场景中外科医生可用单一设备术中检测多种脑肿瘤类型;该数据提示伴随漏检浸润区域或肿瘤的某些风险,但不伴随切除非肿瘤脑组织的风险。

局限性

  • 该模型对浸润性胶质瘤的敏感性有限。
  • 原文结论指出,该数据提示该做法伴随漏检浸润区域或肿瘤的某些风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Infrared (IR) spectroscopy has the potential for tumor delineation in neurosurgery. Previous research showed that IR spectra of brain tumors are generally characterized by reduced lipid-related and increased protein-related bands. Therefore, we propose the exploitation of these common spectral changes for brain tumor recognition. METHODS: Attenuated total reflection IR spectroscopy was performed on fresh specimens of 790 patients within minutes after resection. Using principal component analysis and linear discriminant analysis, a classification model was developed on a subset of glioblastoma (n = 135) and non-neoplastic brain (n = 27) specimens, and then applied to classify the IR spectra of several types of brain tumors. RESULTS: The model correctly classified 82% (517/628) of specimens as "tumor" or "non-tumor", respectively. While the sensitivity was limited for infiltrative glioma, this approach recognized GBM (86%), other types of primary brain tumors (92%) and brain metastases (92%) with high accuracy and all non-tumor samples were correctly identified. CONCLUSION: The concept of differentiation of brain tumors from non-tumor brain based on a common spectroscopic tumor signature will accelerate clinical translation of infrared spectroscopy and related technologies. The surgeon could use a single instrument to detect a variety of brain tumor types intraoperatively in future clinical settings. Our data suggests that this would be associated with some risk of missing infiltrative regions or tumors, but not with the risk of removing non-tumor brain.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Steiner G, Galli R, Preusse G, et al. A new approach for clinical translation of infrared spectroscopy: exploitation of the signature of glioblastoma for general brain tumor recognition. J Neurooncol. 2022. PMID: 36509907. doi:10.1007/s11060-022-04204-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。